{"filing":{"accession_number":"0001193125-26-271117","cik":"0001478320","ticker":"ADPT","company_name":"Adaptive Biotechnologies Corp","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"d65233d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1478320/000119312526271117/d65233d8k.htm"},"events":[{"id":11062,"run_id":9698,"accession_number":"0001193125-26-271117","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The Company announced an intended offering of $250 million in convertible senior notes due 2031 to qualified institutional buyers, with an additional $37.5 million option. Convertible notes are dilutive securities that create potential equity dilution upon conversion. While the filing also mentions a business separation, the primary 8-K disclosure centers on the convertible debt offering, which is a material capital-raising event typical of dilutive issuances.","company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7551,"accession_number":"0001193125-26-271117","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Company announced an intended offering of $250 million in convertible senior notes due 2031 to qualified institutional buyers, with an additional $37.5 million option. Convertible notes are dilutive securities that create potential equity dilution upon conversion. While the filing also mentions a business separation, the primary 8-K disclosure centers on the convertible debt offering, which is a material capital-raising event typical of dilutive issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:17:59.100974+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7551,"accession_number":"0001193125-26-271117","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Company announced an intended offering of $250 million in convertible senior notes due 2031 to qualified institutional buyers, with an additional $37.5 million option. Convertible notes are dilutive securities that create potential equity dilution upon conversion. While the filing also mentions a business separation, the primary 8-K disclosure centers on the convertible debt offering, which is a material capital-raising event typical of dilutive issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:17:59.100974+00:00","company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","filing_date":"2026-06-15"}]}